secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060518
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis AD Phase II/III shows significant cognition improvement; PD topline due June 2024; Q1 cash $3.1M
--------------------------------------------------------------------------------

- Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).
- Phase II/III AD: ADAS-Cog 11 improvement 3.3 pts vs 0.3 for placebo at 3 months; plan 18-month Phase III trial.
- PD Phase III unblinded; topline results expected June 2024; 523 patients randomized, 471 completed.
- Net loss per share $0.10 basic, $0.72 diluted; includes $6.7M non-cash gain from warrant revaluation.
- Filed patent application for buntanetap in neuropsychiatric disorders including autism, ADHD, depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/0001104659-24-060518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/tm2414281d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer